The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

And, in fact, this study showed that the additional palbociclib to this kind of treatment was able to significantly prolong PFS from the start of the maintenance treatment with a benefit in terms of ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.